To avoid the immunosuppressive effects of TGF-β, dominant-negative TGF-βRII was introduced into CAR T cells against the prostate-specific membrane antigen (PSMA) in aggressive human prostate cancer-induced mouse models. The gene discussed is FOLH1; the disease is prostate carcinoma.